You are here: Home / News / TRADE / Apa itu antigen swab test: discharge criteria

Apa itu antigen swab test: discharge criteria

Views: 0     Author: Site Editor     Publish Time: 2022-05-27      Origin: Site

Apa itu antigen swab test: discharge criteria

On January 28, 2020, the National Health Commission informed the discharge standard: the clinical symptoms were relieved, the body temperature was normal, and the two nucleic acid tests were negative, so as to ensure that the discharge was not infectious.

The discharge standard is that the throat swab is negative twice, there are no symptoms, the body temperature is normal, and the CT is normal. After that, it should be isolated for another two weeks. If the anal swabs are required to be normal, the patients will be overstocked and the hospital beds will not be able to turn around. Therefore, it is necessary to closely observe and carry out a hierarchical management for all patients.

Vaccine development

By March 2022, China had provided more than 2.1 billion doses of vaccine to more than 120 countries and internationalantigen combined test kit supplier - UDXBIO organizations, accounting for 1 / 3 of the total global vaccine use outside China.

Inactivated vaccine

On december31,2020, the joint prevention and control mechanism of the State Council was released, and the Sinopharm China new biological crown inactivated vaccine has been approved by the State Food and Drug Administration for listing with conditions.

Inhaled neocoronavirus vaccine

From November 12 to 14, 2021, the world's first inhalable coronavirus vaccine appeared in the "2021 5th Hainan International Health Industry Expo". The world's first inhaled coronavirus vaccine was developed by academician Chen Wei of the Academy of military medicine in cooperation with kangxinuo biological Co., Ltd. the phase II clinical trial has achieved phased results and is promoting the application for emergency use. It is understood that the inhaled neocoronavirus vaccine and intramuscular injection use the same vaccine, and its preparation formula has not changed, but only different administration methods are used. Nebulization inhalation immunization uses the nebulizer to atomize the vaccine into small particles, which enter the respiratory tract and lungs through oral inhalation, so as to stimulate mucosal immunity, which can not be brought about by intramuscular injection.

Therapeutic antibody new drug

In November 2021, the therapeutic antibody new drug js016 jointly developed by the Institute of Microbiology of the Chinese Academy of Sciences and Shanghai Junshi biology was used in combination with another neutralizing antibody, which has been authorized for emergency use in 15 countries around the world.

New crown vaccine enhanced immunization

From 20:00 on January 25, 2022, the registration appointment for enhanced immunization of novel coronavirus vaccine for Hong Kong and Macao compatriots aged 18 and above and the registration appointment for novel coronavirus vaccination for Hong Kong and Macao compatriots aged 3-11 will be started, and the vaccination will begin on January 26.

On April 14, 2022 local time, Pfizer said that the study found that the booster injection of its new coronavirus vaccine for children aged 5 to 11 would produce a "high" immune response.

New crown specific drug

On November 22, 2021, according to the latest news, the clinical phase III of the combination of new crown drugs brii-196 and brii-198 jointly developed by Tsinghua University, Shenzhen Third People's Hospital and tengshengbo pharmaceutical has been unblinded. The administration group achieved zero death after 28 days of treatment, and 8 cases in the control group died. The detailed results will be announced in the near future. This is also the antibody drug with the fastest progress in China, and it is expected to be approved for conditional listing before the end of December. Compared with the new coronavirus antibody drugs approved for emergency use in Europe and America, this drug is the only one that has evaluated the treatment effect of patients infected with mutant strains and obtained data.

In December, 2021, the new crown monoclonal neutralizing antibody ambavir / romisvir combination therapy, which was developed by Professor zhanglinqi, Professor of Tsinghua University School of medicine and director of Tsinghua University Global Health and infectious disease research center and AIDS comprehensive research center, was approved by the China National Drug Administration on December 8, It is used to treat patients with mild and common novel coronavirus infection (covid-19) in adults and adolescents (12-17 years old, weight ≥ 40kg) with high risk factors for progression to severe (including hospitalization or death). Among them, adolescents (12-17 years old, weight ≥ 40kg) with indications are approved with conditions.